The DemTab Study did not improve self-reported guideline adherence in PCP. 3 key findings →
Design: randomized controlled trial Participants: 28 Evidence: high
Full summary, score breakdown and related studies → Original source
32,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
The DemTab Study did not improve self-reported guideline adherence in PCP. 3 key findings →
Design: randomized controlled trial Participants: 28 Evidence: high
Full summary, score breakdown and related studies → Original source
Participants allocated to CR received 10 weekly sessions over 3 months and four maintenance sessions over 6 months. 4 key findings →
Design: randomized controlled trial Participants: 475 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Our results corroborate the positive effect of pb-CT and its maintenance primarily on memory in HE and MCI participants that did not seem to be potentiated by RT. 5 key findings →
Participants: 348 Evidence: high
Full summary, score breakdown and related studies → Original source
The Montreal Cognitive Assessment (MoCA) is an increasingly used screening tool for cognitive impairment. 4 key findings →
Design: case-control study Participants: 710 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Epidemiological and animal studies have suggested that dietary fish or fish oil rich in omega-3 fatty acids (omega3), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), may have effects in psychiatric and behavioral symptoms in Alzheimer's disease (AD). 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Difficulties in the performance of everyday activities were found more frequently in non-demented subjects with mild cognitive deficits than in the general population. 3 key findings →
Design: longitudinal study Participants: 368 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Mild cognitive impairment (MCI) is regarded as a prodrome to dementia. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The scopolamine challenge test is not likely to play a role in the preclinical diagnosis of Alzheimer's disease. 2 key findings →
Design: cohort study Participants: 24 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Apathy is an important and distressing behavioural symptom in Alzheimer's disease and in various neuropsychiatric disorders. 4 key findings →
Design: cross-sectional Participants: 306 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Quality of life (QoL) is becoming an increasingly used outcome measure in both clinical practice and research but little is known about QoL in dementia and how it may change over time. 4 key findings →
Design: longitudinal study Participants: 60 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The Mini-Cog, a composite of three-item recall and clock drawing, was developed as a brief test for discriminating demented from non-demented persons in a community sample of culturally, linguistically, and educationally heterogeneous older adults. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The aim of the study was to investigate the value of the Mini-Mental State Examination (MMSE) for use by general practitioners (GPs) in a group of elderly patients in whom the GPs are considering a dementia diagnosis. 4 key findings →
Design: cross-sectional Participants: 114 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Patterns of cognitive impairment may be detected in cases of AD 2 years before formal clinical diagnosis, although high education level prolongs competence, principally on verbal tasks. 3 key findings →
Participants: 150 Evidence: moderate
Full summary, score breakdown and related studies → Original source
From a prospective Memory Clinic cohort including consecutively referred patients, age 60 years or above, and with MMSE score 20 or above, 36 patients with AD and 30 with MCI were included in this study. 4 key findings →
Participants: 36 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
As elderly populations grow, dementia detection in the community is increasingly needed. 4 key findings →
Participants: 249 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cholinesterase inhibitors with additional nicotinic activity, such as galantamine, may be useful in PD patients with dementia (PDD) since stimulation of nicotinic receptors may prevent the down-regulation that is likely to accompany cholinesterase inhibition and facilitate dopamine release in the striatum. 4 key findings →
Design: open-label trial Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
RAVLT was administered as part of a more extensive neuropsychological battery at baseline evaluation in 116 unselected patients referred by subjective memory complaints (SMC). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We surveyed the medical records of outpatients meeting the NINCDS-ADRDA criteria for probable DAT who were able to complete the Cognitive Difficulties Scale (CDS) and had a close informant relative (IR) who could complete the family form of the same questionnaire. 4 key findings →
Participants: 88 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The purpose of this study was to explore the structure of the Zarit Burden Interview (ZBI) for informal caregivers of patients suffering from AD or related disorders, and to examine the relations of the dimensions found with functional disabilities and other patient health indicators. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In addition, we examined whether anosognosia had an impact on the agreement between patient and informant ratings of QoL and whether anosognosia, dementia severity, depression and behavioural symptoms were significantly correlated to QoL in early AD. 4 key findings →
Participants: 48 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Mild Cognitive Impairment (MCI) is a borderline state between age-associated cognitive decline and mild dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Retrospective analysis of clock drawing performance using three published scoring methods (Shulman, Sunderland and Wolf-Klein). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Mild cognitive impairment (MCI) represents a transitional state between normal aging and dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The main hypothesis was that subtle vitamin B12 deficiencies occur more commonly in senile dementia of Alzheimer type (SDAT) that in healthy elderly individuals, and may be revealed by elevated total serum homocysteine (tHcy). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The psychosocial burden was recorded by the 15-item Relatives' Stress Scale (RSS). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 32,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 32,580 records, built mostly from automated pulls of Europe PMC (66.9% of the library) and OpenAlex (15.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,045 records (3.2% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events
Last updated